| Sage Restructuring Halves Staff, Turns Focus to Failed Depression Drug | Frank Vinluan | 04/07/20 | Boston |
| Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More | Ben Fidler | 09/13/19 | National |
| The Winners of the 2019 Xconomy Awards Boston Are… | Jeff Bauter Engel | 09/12/19 | Boston |
| The Finalists for the 2019 Xconomy Awards Are … | Angela Shah | 07/10/19 | Boston |
| Sage Hits Mark in Postpartum Depression Phase 3 Trial, Stock Surges | Corie Lok | 01/07/19 | Boston |
| Xconomy Awards 2018 Gala Honors the Best of Boston Life Science: Slideshow | Corie Lok | 10/11/18 | Boston |
| The Art of Perseverance: Meet Xconomy’s Six CEO Award Finalists | Ben Fidler | 07/02/18 | Boston |
| The 2018 Xconomy Awards Finalists Are… | Corie Lok | 06/28/18 | Boston |
| Sage Speeds Ahead With Plans For a Short-Course Depression Drug | Ben Fidler | 06/12/18 | Boston |
| Sage Shares Soar Again As Depression Drug Hits Mark in Phase 2 Test | Ben Fidler | 12/07/17 | Boston |
| Sage Bounces Back, Eyes FDA Filing for Postpartum Drug | Ben Fidler | 11/09/17 | Boston |
| All Eyes on Depression Trials as Sage Neuro Drug Flunks Epilepsy Test | Ben Fidler | 09/12/17 | Boston |
| Bio Roundup: CRISPR Drama, Marathon and PhRMA, the Price of Vision & More | Ben Fidler | 02/17/17 | National |
| Caveats But No “Quicksand” In Sage’s Positive Postpartum Trial Data | Alex Lash | 07/12/16 | Boston |
| With Positive Postpartum Results, Sage Ponders More Mood Disorders | David Holley | 07/12/16 | Boston |
| East Coast Biotech Roundup: X4, Rgenix, Alnylam, Intellia & More | Ben Fidler | 09/04/15 | Boston |
| Sage Points to Tremor Data to Back Up “De-Risked” Neuro Drug Plan | Ben Fidler | 09/03/15 | Boston |
| East Coast Biotech Roundup: Vertex, Moderna, Sage, ASCO & More | Ben Fidler | 05/15/15 | Boston |
| Sage Preps For Final Test As Epilepsy Drug Holds Up in Small Study | Ben Fidler | 05/14/15 | Boston |
